Ivarmacitinib for teens and adults with atopic dermatitis
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new oral medication (Ivarmacitinib) for people aged 12–75 with moderate-to-severe atopic dermatitis (a chronic skin condition causing red, itchy skin). The goal is to see if it improves symptoms safely in both adolescents and adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 75 years old
- You must have moderate-to-severe atopic dermatitis
- You must be able to understand and talk with the study team
- You cannot have certain blood test abnormalities (low white blood cell count, low hemoglobin, etc.)
- You cannot have active serious infections like tuberculosis or hepatitis
- Women who are pregnant, breastfeeding, or planning pregnancy cannot take part
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called ivarmacitinib for people with moderate-to-severe atopic dermatitis (severe itchy, inflamed skin) who haven't seen enough improvement from other similar treatments. Researchers want to see if switching to this new drug helps control symptoms better.
This trial tests a drug called Ivarmacitinib for people whose solid tumors stopped responding to immunotherapy due to side effects. It aims to see if Ivarmacitinib can help control the tumor while managing those side effects.
This trial tests a once-daily pill called Ivarmacitinib (a JAK inhibitor) taken alone to see if it can improve symptoms in people with rheumatoid arthritis who have not responded well to standard treatments like methotrexate. The study aims to find a more effective option for those who need better control of their RA.
This trial tests a new daily pill, ivarmacitinib, for people with polymyalgia rheumatica (PMR). It may help control symptoms without needing steroids long-term.
This trial tests if a drug called Ivarmacitinib can prevent graft-versus-host disease (a common complication where donor cells attack your body) after a stem cell transplant from a half-matched donor. It is for people with certain blood cancers who are about to receive a transplant.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.